Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) – Analysts at Jefferies Financial Group increased their FY2018 earnings per share estimates for Roche Holdings AG Basel in a research report issued to clients and investors on Friday, October 12th. Jefferies Financial Group analyst I. Hilliker now expects that the company will post earnings per share of $2.23 for the year, up from their previous estimate of $2.11.
Other analysts have also recently issued reports about the stock. ValuEngine cut shares of Roche Holdings AG Basel from a “hold” rating to a “sell” rating in a research note on Tuesday, August 7th. Cowen reaffirmed a “buy” rating and issued a $34.00 target price on shares of Roche Holdings AG Basel in a research note on Thursday, July 26th. Zacks Investment Research raised shares of Roche Holdings AG Basel from a “hold” rating to a “strong-buy” rating and set a $35.00 target price for the company in a research note on Wednesday, September 12th. Finally, Bank of America cut shares of Roche Holdings AG Basel from a “buy” rating to a “neutral” rating in a research note on Monday, September 10th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $34.50.
RHHBY stock opened at $29.68 on Monday. The company has a market capitalization of $205.55 billion, a price-to-earnings ratio of 15.22, a PEG ratio of 1.83 and a beta of 0.62. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.28 and a quick ratio of 0.97. Roche Holdings AG Basel has a one year low of $26.30 and a one year high of $32.42.
Several hedge funds and other institutional investors have recently made changes to their positions in RHHBY. Gardiner Nancy B purchased a new stake in shares of Roche Holdings AG Basel during the 3rd quarter valued at $454,000. Chartwell Investment Partners LLC purchased a new stake in shares of Roche Holdings AG Basel during the 2nd quarter valued at $743,000. Chickasaw Capital Management LLC grew its stake in shares of Roche Holdings AG Basel by 5.0% during the 2nd quarter. Chickasaw Capital Management LLC now owns 42,000 shares of the company’s stock valued at $1,166,000 after buying an additional 2,000 shares during the period. Jolley Asset Management LLC purchased a new stake in shares of Roche Holdings AG Basel during the 2nd quarter valued at $1,576,000. Finally, PVG Asset Management Corp purchased a new stake in shares of Roche Holdings AG Basel during the 1st quarter valued at $2,218,000. 0.57% of the stock is owned by institutional investors.
Roche Holdings AG Basel Company Profile
Roche Holding AG diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.
Further Reading: Intrinsic Value and Stock Selection
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.